PORTON DOWN, England and SAN FRANCISCO, Dec. 2 /PRNewswire/ -- Enigma Diagnostics, the decentralized and point-of-care molecular diagnostics company, announced today the opening of a new U.S. office in San Francisco and the appointment of Chris Melancon as Vice President, Business Development.
The San Francisco office opened on December 1 and is Enigma’s first overseas facility established to commercialize Enigma’s range of rapid diagnostic instrument systems. Enigma’s first product, the Enigma Field Laboratory (FL), was launched in November, and is a fully automated, real-time PCR (polymerase chain reaction) detection system designed for in-field testing by veterinarians, first responders and military personnel.
Chris Melancon will lead the new office and joins Enigma with more than 16 years experience in life sciences and information technology industries, including senior positions at Applied Biosystems and Siebel Systems, a division of Oracle Corporation. His work in emerging markets included biological and influenza surveillance and pathogen detection.
During his three-year tenure at ABI, Chris managed the large scale PCR reagents business for anthrax testing at U.S. Postal Service facilities and commercialized additional pathogen detection kits for European Union customers. He is a graduate of the U.S. Military Academy at West Point and Tulane University’s Freeman School of Business.
“The opening of the San Francisco office and Chris’ appointment underpins our commitment to a U.S. commercialization strategy as we expand our operations internationally. We are very pleased to have Chris with his proven track record join Enigma at this important stage of our growth,” stated John McKinley, Chairman of Enigma Diagnostics.
About Enigma Diagnostics Limited
Enigma Diagnostics Limited is a private UK based company specializing in developing the next generation of rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.
Enigma’s innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.
The Company is targeting a number of multi-billion dollar markets, core among which are the Clinical and high value Applied Markets. Enigma’s commercialization strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.
Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialization of real-time PCR instruments. Enigma’s R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including U.S., EU and Japan with more extensive filing and grants across a number of other key territories.
For more information visit www.enigmadiagnostics.com
CONTACT: UK: Enigma Diagnostics, Deborah Cordingley, +44-1980-590131,
deborah.cordingley@enigmadiagnostics.com, or U.S.: Megan Dubrowski - Media,
mdubrowski@rlcinc.com, or Cecelia Heer - Investors, cheer@rlcinc.com, both
of Richard Lewis Communications, Inc., +1-212-827-0020, for Enigma
Diagnostics Limited
Web site: http://www.enigmadiagnostics.com/
